ALC Alcon Vision: EV/EBITDA Multiple

Corporate company logo of alcon.com (ALC)

Alcon Inc. growth is fueled by an aging population and demand for premium optics. The EV/EBITDA value, accounting for total debt, reflects the current market valuation, where 16.32 serves as the final level mark. Automated hubs ensure stability, although global expansion requires accounting for geopolitical risks and potential disruptions in component supplies from Asia.

ALC Alcon Inc: Total Company Value to Operating Income Before Depreciation Ratio in the range 11/23/2025 - 11/10/2026

alcon.com (ALC) - metric breakdowns and financial figures

- stock price and consensus target price:
Stock Quotes Alcon Vision|ALC - Average Forecast Price
- company stock capitalization data:
Market Capitalization Alcon Corp|ALC - Total Enterprise Value
- issuer book value statistics:
Net Assets per Single Share Alcon|ALC - Book Valuation of Business|Market Capitalization to Book Value Ratio alcon.com|ALC - Company Total Assets
- debt and liquidity data:
Debt to Equity Alcon Inc.|ALC - Long-Term Debt to Equity|Short-Term Debt to Capital Alcon|ALC - Company Total Debt|Debt to Book Capitalization Ratio Alcon Corp|ALC - Long-Term Debt|Company Short-Term Debt Alcon|Quick Liquidity Indicator alcon.com
- business earnings and investment ratios data:
ALC - Final Profit|Projected Future Earnings Alcon Inc.|ALC - Business Payback Period|Future Price to Earnings Alcon Inc.|ALC - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Alcon Corp|ALC - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Alcon|ALC - Net earnings per share for the last four quarters|Quarterly EPS earnings growth alcon.com|ALC - Earnings growth in current year|Net earnings per share growth forecast for next year Alcon Inc.
Analysis of all company metrics:ALC (Alcon Vision)
Original product of alcon.com

For Alcon Inc. (ALC), this indicator is critically important due to the capital intensity of ophthalmic equipment production. The metric compares the total enterprise value, including net debt, with EBITDA, determining the real value of assets regardless of tax regimes. By analyzing the EV/EBITDA trend of the business, an investor can identify stock overvaluation amid logistical disruptions and sanction restrictions. This allows for an assessment of the issuer's resilience to external shocks.

Competitor analysis

Bausch + Lomb Corp - Enterprise Value to EBITDA Ratio|Glaukos Medical (GKOS) - Company Value to EBITDA|Apellis Pharmaceuticals - EV/EBITDA Multiple|Company Value to EBITDA Belite Bio Inc|Ocular Therapeutix, Inc. (OCUL) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|HROW - Total Company Value to Operating Income Before Depreciation Ratio|VRDN (Viridian Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple LENZ Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Oculis (OCS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization EYPT (eyepointpharma.com)|EV/EBITDA Multiple KOD (Kodiak Sciences)|ALDX - Enterprise Value to EBITDA Ratio|KALA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Opus Genetics Inc|okyopharma.com (OKYO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation ADVM|Enterprise Value to EBITDA Ratio OTLK|CLSD: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple NBY|Total Company Value to Operating Income Before Depreciation Ratio kiorapharma.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alimera Sciences, Inc. ALIM|EYEN: Enterprise Value to Operating Income Before Depreciation|Guardion Health Sciences - EV/EBITDA Multiple|Ocuphire Pharma Inc (OCUP) - Enterprise Value to EBITDA Ratio|OPT (Opthea Ltd.) - Enterprise Value to EBITDA Ratio